Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108

摘要: Purpose Aurora A kinase (AAK) is upregulated in highly proliferative lymphomas, suggesting its potential as a therapeutic target. Alisertib novel oral AAK inhibitor without adverse safety signals early-phase studies that demonstrated preliminary activity T-cell lymphoma. This phase II study was conducted to further investigate the efficacy of alisertib relapsed or refractory peripheral non-Hodgkin lymphoma (PTCL). Patients and Methods Eligible patients with histologically confirmed relapsed/refractory PTCL transformed Mycosis fungoides (tMF) received 50 mg twice day for 7 days on 21-day cycles. Results Of 37 eligible patients, histologic subtypes enrolled included not otherwise specified (n = 13), angioimmunoblastic 9), tMF 7), adult lymphoma/leukemia 4), anaplastic large-cell 2), extranodal natural killer/T-cell 2). Grade 3 4 events ≥ 5% neutropenia (32%),...